Delivery Order SPE2DB22D1106-SPE2DB25FFGD1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $76,250.75 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract type. The award, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competed delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $17,638.89 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive award status. The contract is set to complete on August 12, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $5,846.07 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with a completion date of August 22, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract is valued at $11,191.56 with a firm fixed price structure and carries an ultimate completion date of August 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $40,276.41 by the Defense Logistics Agency on August 4, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $74,636.43 for RINVOQ ER 45 mg tablets (28-count units) on August 5, 2025, with completion targeted for August 6, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal vendor, fulfills this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,565.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFGD1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $37,122.24 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This firm fixed-price delivery order is scheduled for completion by September 2, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other government agencies. RINVOQ ER is a specialty rheumatoid arthritis medication, consistent with AmerisourceBergen's portfolio of advanced pharmaceutical products delivered through its extensive federal contract vehicles serving the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.1k | 8/29/25 |